TOP PHARM CO.,LIMITED

About Us
Factory Tour
Quality Control
Contact Us
Home ProductsOral Anabolic Steroids

99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity

99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity

  • 99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity
  • 99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity
  • 99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity
  • 99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity
99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity
Product Details:
Place of Origin: China
Brand Name: Top Pharm
Certification: IOS 901
Model Number: 168273-06-1
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Price: Negotiable
Packaging Details: As your requirments
Delivery Time: 3-6 working days
Payment Terms: T/T, Western Union, MoneyGram,bitcoin
Supply Ability: bulk stock
Contact Now
Detailed Product Description
Purity: 99% Appearance: White Loose Lyophilized Powder.
Spec: 10G CAS: 168273-06-1
MF: C22H21Cl3N4O MW: 463.79
High Light:

Anti Obesity Oral Anabolic Steroids

,

Rimonabant Oral Anabolic Steroids

Rimonabant

Other name: Acomplia
CAS: 168273-06-1
MF: C22H21Cl3N4O
MW: 463.79
Purity:99.5%


 

 

Rimonabant

 

From Wikipedia, the free encyclopedia
 
 
 
Jump to navigationJump to search
Rimonabant
 
 
Clinical data
AHFS/Drugs.com Consumer Drug Information
License data
Pregnancy
category
  • Not assigned, use not recommended
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Withdrawn from European and Brazilian markets; not approved elsewhere[1][2]
Pharmacokinetic data
Bioavailability Undetermined
Protein binding Nearly 100%
Metabolism Hepatic, CYP3A4 involved
Elimination half-life Variable:
6 to 9 days with normal BMI
16 days if BMI >30
Excretion Fecal (86%) and renal (3%)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.210.978 Edit this at Wikidata
Chemical and physical data
Formula C22H21Cl3N4O
Molar mass 463.79 g·mol−1
3D model (JSmol)
(verify)

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti)[3] is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.

History[edit]

Rimonabant is a selective CB1 receptor blocker and was discovered and developed by Sanofi-Aventis;

On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union as a prescription drug for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m2, or patients with a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.It was first in its class to be approved anywhere in the world.

Rimonabant was submitted to the Food and Drug Administration (FDA) for approval in the United States in 2005; in 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval and two weeks later the company withdrew the application.

The drug was approved in Brazil in April 2007.

In October 2008, the European Medicines Agency recommended the suspension of Acomplia after the Committee for Medicinal Products for Human Use (CHMP) had determined that the risks of Acomplia outweighed its benefits due to the risk of serious psychiatric problems, including suicide. In November 2008 an advisory committee in Brazil recommended suspension as well, and that month Sanofi-Aventis suspended sale of the drug worldwide. The EMA approval was withdrawn in January 2009. In 2009 India prohibited the manufacture and sale of the drug.

Adverse effects[edit]

Data from clinical trials submitted to regulatory authorities showed that rimonabant caused depressive disorders or mood alterations in up to 10% of subjects and suicidal ideation in around 1%, and in Europe it was contraindicated for people with any psychiatric disorder, including depressed or suicidal individuals.

Additionally, nausea and upper respiratory tract infections were very common adverse effects (occurring in more than 10% of people); common adverse effects (occurring in between 1% and 10% of people) included gastroenteritis, anxiety, irritability, insomnia and other sleep disorders, hot flushes, diarrhea, vomiting, dry or itchy skin, tendonitis, muscle cramps and spasms, fatigue, flu-like symptoms, and increased risk of falling.

The FDA's advisory committee raised concerns that based on animal data, it appeared that the therapeutic window with regard to CNS toxicity, and specifically seizures was almost nonexistent; the therapeutic dose and the dose that caused seizures in animals appeared to be the same.

When the EMA reviewed postmarketing surveillance data, it found that the risk of psychiatric disorders in people taking rimonabant was doubled.

Pharmacology[

Pharmacodynamics

Rimonabant is an inverse agonist of the cannabinoid CB1 receptor. Originally thought to be selective for the CB1 receptor, rimonabant was subsequently also found to act as an antagonist of the μ-opioid receptor.

Chemistry

The chemical synthesis of rimonabant is described as follows:[17][failed verification]

 

 

 

Polypeptide Hormones we supply
Melanotan II CAS 121062-08-6 timulate the body's tanning response
Selank CAS 129954-34-3 help enhance mental sharpness,enhance memory
DSIP CAS 62568-57-4 Delta sleep-inducing peptide, abbreviated DSIP
Gonadotropin CAS 71447-49-9 Mainly used for prostate cancer
Tesamorelin CAS 218949-48-5 used in the treatment of HIV-associated lipodystrophy
Triptorelin CAS 57773-63-4 used as the acetate or pamoate salts
HG 176-191   the fat-reducing effects
Pentadecapeptide BPC 157 CAS 137525-51-0 increasing lean muscular tissue mass, reducing fat
TB500 CAS 77591-33-4 oincrease muscle growth
Oxytocin CAS 50-56-6 used for stimulation of uterus contractions
Sermorelin CAS 86168-78-7 Increases the development of lean body mass
Hexarelin CAS 140703-51-1 the treatment of growth hormone secretion deficiency
Ipamorelin CAS 170851-70-4 a selective growth hormone secretagogue
Melanotan 1 CAS 75921-69-6 endogenous melanocortine peptide
MGF   used by bodybuilders and athletes
PEG-MGF   cause site specific muscle growth
CJC-1295 Without DAC CAS 863288-34-0 increasing binding affinity to the GHRH receptors
CJC-1295 with DAC CAS 863288-34-0 improved physique and sense of well being
PT-141   increase libido effects of both men and women
GHRP-2 CAS 158861-67-7 growth hormone stimulation
GHRP-6 CAS 87616-84-0 Increase in strength,Muscle mass,Body fat loss
Tb-500 CAS 77591-33-4 increases in endurance,strength and muscle growth

 

 

 

 

 

 

99% Purity Rimonabant CAS 168273-06-1 White Powder Anorexia And Anti Obesity 9

Contact Details
TOP PHARM CO.,LIMITED

Contact Person: Baron

Tel: +8618627186113

Send your inquiry directly to us (0 / 3000)